Yabao Pharmaceutical Group Co., Ltd.

On Chemball

My Chemball

As Supplier

My RFQ Manage Products

As Buyer

My RFQ Post RFQ

My Account

+86-571-8627 3270

Yabao Pharmaceutical Group Co., Ltd.

46 YRS

Shanxi, China

CNY 770 Million

2997000 m²

Over 1000 people

Main Products: Aniracetam / Troxerutin / Nimodipine / Dihydralazine Sulphate / Magnesium Trisilicate

Shanxi, China

Contact Supplier

Home Company Profile Contact Us Post Buying Request

ABOUT US

Yabao Pharmaceutical Group Co., Ltd. is the first listed pharmaceutical company in Shanxi Province and one of the first batch of recognized high-tech enterprises. Integrating R&D, production, logistics, distribution and planting of traditional Chinese medicines, Yabao has 21 branches andsubsidiariesand over 5600 employees in total. Among over 5030 domesticpharmaceutical enterprises, Yabao’s comprehensive strength ranks 87th, bing accredited by the Ministry of Industry as China top 100 pharmaceutical enterprise; its innovation power is in top 20, being regarded as China’sbest industrial enterprise for for pharmaceutical R&D product line. The trademark of "Yabao" has become an China renowned brand Yabao has 9 production bases in Beijing, Shanghai, Taiyuan, Chengdu, Guiyang, Yuncheng, America and etc, 4R&D bases, 2 traditional Chinese medicine planting bases. All the 9 production bases have passed the new GMP certification,with, Beijing Yabao Biopharma having passed the cGMP certification and the No. 3 Branch passed EU GMP certification. The main products include Chinese and western mediciness, APIs and pharmaceutical packaging materials, and the like of over 300 varieties in total. The products for chronic diseases in elderly and for women and children take a very high share. The patent product, Diarrago, is a national famous-brand. It was awarded the first class prize of science and technology by China Association of Chinese Medicine in 2006. and ranked the first in Chinese over-the-counter products in 2015. It is the first brand of drug for children's external use in China, with market share more than 90%. The company has a globlized professionalR&D team, which is composed of 460 R&D staff in total , including 22 Dr. and 150 Masters. Yabao has taken steps to international practice in new drug application, production and distribution,following the international strategy of ”researchin China and declaration in China,USA and Europe; production in China and distribution in China, USA and Europe”. With more than 3000 salesman, Yabao has established professional marketing teams for business channels, OTC retail, terminal at the grass-roots level, hospital investment, OTC investment, APIs, sales development, Beijing biological Pharma, health care consumer products and etc. The company has perfect sales network, which covers the first, secondary and third markets and terminal markets in 661 counties of 32 provinces and cities. In the period of "the 13th of Five-year Plan", Yabao “takes pharmaceutical products as priority withhealth products and medical services as assistance". on the one hand, it further develops industry and on the other hand, makes full use of capital to promotes its rapid development through internal "assets operation" and external "capital operation". Through building 5 centers, 10 systems, and 6 abilities, Yabao strives to realize 6 transformations to finally become the leader in children's big health industry,the most innovative pharmaceutical company in China and the internationalization model in Chinese pharmaceutical industry.

Basic Information